Mabgeek

Executive Summary

Mabgeek is a preclinical-stage biotechnology company based in Suzhou, China, specializing in antibody discovery and engineering. Founded in 2013, the company operates with a hybrid model offering contract research services to external partners while also advancing its own proprietary biologic candidates. Mabgeek leverages advanced antibody technologies to develop novel monoclonal and engineered antibodies targeting oncology and inflammatory diseases. Despite its small size (1-50 employees), the company has established a solid foundation in antibody engineering, positioning itself to potentially emerge as a player in the competitive biotech landscape. However, with no disclosed financials, valuation, or specific pipeline details, the company remains at an early stage with limited public visibility. Its success will depend on advancing its own candidates into formal preclinical development and securing partnerships or funding to support these efforts.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate IND-enabling studies initiation40% success
• Q4 2026Strategic partnership or licensing deal for antibody platform55% success